
24 Feb 2022
Hikma Pharmaceuticals: Superb FY21 and a solid outlook for FY22
This content is only available within our institutional offering.

Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
Hikma Pharmaceuticals: Superb FY21 and a solid outlook for FY22
Hikma Pharmaceuticals Plc (HIK:LON) | 1,833 -91.7 (-0.3%) | Mkt Cap: 4,067m
- Published:
24 Feb 2022 -
Author:
Stefan Hamill | Paul Cuddon | Kane Slutzkin -
Pages:
4 -